Author

Gianmaria Minervini

Observed name: G. Minervini

Institution: AstraZeneca (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), AstraZeneca (United States)

OpenAlex ID: A5042690795

Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine

2016 · Jessica A. Hiemstra, Dong I. Lee, et al. · Journal of the American Heart Association · 33

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults

2009 · Pierre Van Damme, Gianmaria Minervini, et al. · Human Vaccines · 27

Saxagliptin Prevents Increased Coronary Vascular Stiffness in Aortic-Banded Mini Swine

2018 · Bradley S. Fleenor, An Ouyang, et al. · Hypertension · 17

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates

2012 · Gianmaria Minervini, Barbara J. McCarson, et al. · Vaccine · 7

Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials

2014 · William Cook, Gianmaria Minervini, et al. · Postgraduate Medicine · 4

Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia

2014 · Matthew L. Mintz, Gianmaria Minervini · Current Medical Research and Opinion · 4

P1145 Efficacité et sécurité à long terme de la saxagliptine en trithérapie avec de l’insuline et de la metformine dans le diabète de type 2

2013 · B. Charbonnel, A. Barnett, et al. · Diabetes & Metabolism

Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Modified Process in Healthy Young Adults

2007 · Gianmaria Minervini · 45th Annual Meeting

Works count: 8

Citation count: 92

H-index: 4

I10-index: 3